Table 2.
Final multivariable Cox models associated with nomogram for overall survival and progression-free survival
| Variable | OS |
PFS |
||||||
|---|---|---|---|---|---|---|---|---|
| Coefficient | SE | HR (95% CI) | P* | Coefficient | SE | HR (95% CI) | P* | |
| Age, y | <.001 | .03 | ||||||
| −0.0012 | 0.0017 | † | −0.0036 | 0.0015 | † | |||
| 0.0078 | 0.0020 | 0.0045 | 0.0018 | |||||
| Sex | .01 | .04 | ||||||
| Female | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| Male | 0.0442 | 0.0186 | 1.05 (1.01 to 1.09) | 0.0342 | 0.0167 | 1.04 (1.00 to 1.06) | ||
| Body mass index, kg/m2 | † | <.001 | .001 | |||||
| −0.0236 | 0.0046 | −0.0133 | 0.0042 | † | ||||
| 0.0167 | 0.0055 | 0.0101 | 0.0049 | |||||
| Performance status | <.001 | <.001 | ||||||
| 0 | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| 1 | 0.2663 | 0.0184 | 1.31(1.25 to 1.34) | 0.1599 | 0.0166 | 1.17 (1.13 to 1.20) | ||
| 2+ | 0.5471 | 0.0407 | 1.73 (1.58 to 1.84) | 0.3358 | 0.0395 | 1.40 (1.29 to 1.49) | ||
| Prior chemotherapy | <.001 | <.001 | ||||||
| No | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| Yes | 0.1358 | 0.0237 | 1.15 (1.10 to 1.20) | 0.1124 | 0.0211 | 1.12 (1.08 to 1.17) | ||
| KRAS mutation status | <.001 | <.001 | ||||||
| Wild-type | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| Mutant | 0.3000 | 0.0181 | 1.35 (1.30 to 1.39) | 0.2623 | 0.0163 | 1.30 (1.25 to 1.33) | ||
| BRAF mutation status | <.001 | <.001 | ||||||
| Wild-type | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| Mutant | 0.7922 | 0.0304 | 2.21 (2.09 to 2.34) | 0.6125 | 0.0285 | 1.85 (1.73 to 1.92) | ||
| Platelets, ×109/L | <.001 | <.001 | ||||||
| 0.0012 | 0.0002 | † | 0.0009 | 0.0002 | † | |||
| −0.0013 | 0.0003 | −0.0009 | 0.0002 | |||||
| White blood cells, ×109/L | 0.0063 | 0.0027 | 1.01 (1.00 to 1.01) | .01 | − | − | − | ‡ |
| Hemoglobin, g/dL | −0.0449 | 0.0063 | 0.96 (0.94 to 0.97) | <.001 | −0.0229 | 0.0056 | 0.98 (0.97 to 0.99) | <.001 |
| Albumin, g/L | <.001 | <.001 | ||||||
| −0.0481 | 0.0032 | † | −0.0273 | 0.0031 | † | |||
| 0.0097 | 0.0036 | 0.0097 | 0.0032 | |||||
| Absolute neutrophil count, ×109/L | <.001 | <.001 | ||||||
| 0.1129 | 0.0069 | † | 0.0274 | 0.0033 | 1.03 | |||
| −0.0767 | 0.0118 | |||||||
| Bilirubin, mg/dL | <.001 | <.001 | ||||||
| 0.4842 | 0.0758 | † | 0.2376 | 0.0679 | † | |||
| −0.5016 | 0.0831 | −0.2332 | 0.0745 | |||||
| No. of met sites | <.001 | <.001 | ||||||
| 0–1 | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| 2+ | 0.1859 | 0.0224 | 1.20 (1.16 to 1.26) | 0.1103 | 0.0247 | 1.12 (1.07 to 1.17) | ||
| Liver metastases | <.001 | <.001 | ||||||
| No | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| Yes | 0.1811 | 0.0240 | 1.20 (1.15 to 1.26) | 0.1304 | 0.0230 | 1.14 (1.09 to 1.19) | ||
| Lymph node metastases | <.001 | <.001 | ||||||
| No | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| Yes | 0.1375 | 0.0214 | 1.15 (1.10 to 1.19) | 0.0740 | 0.0206 | 1.08 (1.04 to 1.12) | ||
| Peritoneal metastases | <.001 | .01 | ||||||
| No | – | – | 1.00 (reference) | – | – | 1.00 (reference) | ||
| Yes | 0.1706 | 0.0248 | 1.19 (1.13 to 1.23) | 0.0586 | 0.0242 | 1.06 (1.02 to 1.11) | ||
| Lung metastases | − | − | − | ‡ | <.001 | |||
| No | – | – | 1.00 (reference) | |||||
| Yes | 0.1029 | 0.0204 | 1.11 (1.07 to 1.15) | |||||
*
P values were calculated using Wald chi-square tests; the P values are two-sided. Only variables that contributed statistically significantly to final models are included in the table. Derived neutrophil to lymphocyte ratio and tumor location were significant on univariate analyses but did not contribute to the final model. CI = confidence interval; HR = hazard ratio; OS = overall survival; PFS = progression-free survival.
†
Single hazard ratio not available due to nonlinear effect for these continuous variables.
‡
Variables did not statistically significantly contribute to their respective models.